A detailed history of E Fund Management Co., Ltd. transactions in Cytokinetics Inc stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 15,927 shares of CYTK stock, worth $837,919. This represents 0.05% of its overall portfolio holdings.

Number of Shares
15,927
Previous 6,591 141.65%
Holding current value
$837,919
Previous $462,000 86.58%
% of portfolio
0.05%
Previous 0.03%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$47.86 - $75.05 $446,820 - $700,666
9,336 Added 141.65%
15,927 $862,000
Q1 2024

May 13, 2024

SELL
$63.75 - $108.06 $477,742 - $809,801
-7,494 Reduced 53.21%
6,591 $462,000
Q4 2023

Feb 06, 2024

BUY
$26.88 - $83.49 $37,739 - $117,219
1,404 Added 11.07%
14,085 $1.18 Million
Q3 2023

Nov 13, 2023

BUY
$29.46 - $36.61 $18,235 - $22,661
619 Added 5.13%
12,681 $374,000
Q2 2023

Aug 11, 2023

BUY
$32.62 - $40.75 $39,600 - $49,470
1,214 Added 11.19%
12,062 $393,000
Q1 2023

May 11, 2023

SELL
$33.36 - $45.71 $31,958 - $43,790
-958 Reduced 8.11%
10,848 $382,000
Q4 2022

Feb 14, 2023

BUY
$35.77 - $51.11 $109,742 - $156,805
3,068 Added 35.11%
11,806 $541,000
Q3 2022

Nov 14, 2022

SELL
$38.54 - $54.52 $90,491 - $128,012
-2,348 Reduced 21.18%
8,738 $423,000
Q2 2022

Aug 15, 2022

BUY
$33.93 - $48.92 $133,412 - $192,353
3,932 Added 54.96%
11,086 $436,000
Q1 2022

May 12, 2022

BUY
$29.74 - $46.0 $69,889 - $108,100
2,350 Added 48.92%
7,154 $263,000
Q4 2021

Feb 11, 2022

SELL
$34.35 - $46.38 $35,586 - $48,049
-1,036 Reduced 17.74%
4,804 $219,000
Q3 2021

Nov 12, 2021

SELL
$18.54 - $35.74 $4,375 - $8,434
-236 Reduced 3.88%
5,840 $209,000
Q1 2021

May 12, 2021

BUY
$18.57 - $25.68 $112,831 - $156,031
6,076 New
6,076 $141,000

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.95B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.